Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cyclacel Pharmaceuticals Inc
CYCCP | US
7.30
USD0
0%
CYCCP | US
About Cyclacel Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
7.30
Open
7.30
High
7.30
Low
7.30
Cyclacel Pharmaceuticals Inc. a clinical-stage biopharmaceutical company develops medicines for the treatment of cancer and other proliferative diseases. The company's lead product includes fadraciclib a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib a polo-like kinase inhibitor program which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies including chronic lymphocytic leukemias acute myeloid leukemias myelodysplastic syndromes and other advanced leukemias. The company is headquartered in Berkeley Heights New Jersey
View LessCYCCP | US
Risk
78.6
Sharpe
-0.35
Luna's Score
46/100
Recommendation
Hold
Luna says (CYCCP | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
78.6%1 month
78.6%3 months
85.2%6 months
166.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
-
Debt to equity
0.01
Debt to assets
0.00
Ent. to EBITDA
-
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-20.18M
MarketCap
13.88M
MarketCap(USD)
13.88M
Div. yield
8.22
Op. margin
-91.10K
Erngs. growth
-
Rev. growth
-98.90
Ret. on equity
-570.69
Short ratio
-
Short perc.
-
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
1.67
Range1M
1.95
Range3M
6.20
Volumes: Market Activity
Rel. volume
0.04
Price X volume
540.20
